Trials / Completed
CompletedNCT00387270
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Medivation, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimebon | Dimebon 10 or 20 mg TID x 7 days |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2006-10-12
- Last updated
- 2008-01-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00387270. Inclusion in this directory is not an endorsement.